Skip to main content
رجوع
GLUE logo

Monte Rosa Therapeutics, Inc.

جودة البيانات: 100%
ذروة بيع
GLUE
NASDAQ Healthcare Biotechnology
KWD 14.72
▼ KWD 0.31 (-2.06%)
القيمة السوقية: 958.61M
نطاق اليوم
KWD 14.20 KWD 14.92
نطاق 52 أسبوعًا
KWD 3.50 KWD 25.77
حجم التداول
1,627,964
متوسط 50 يوم / 200 يوم
KWD 19.78 / KWD 11.73
الإغلاق السابق
KWD 15.03

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -24.8 0.3
P/B 4.1 2.9
ROE % -16.9 3.7
Net Margin % -31.2 3.8
Rev Growth 5Y % 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

Hold
KWD 31.750 +115.7%
Low: KWD 22.000 High: KWD 37.000
ربحية السهم المستقبلية
-KWD 1.520
الإيرادات المقدّرة
57 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 1.602
-KWD 4.149 – -KWD 0.189
170 M 1
FY2029 -KWD 2.126
-KWD 5.506 – -KWD 0.251
120 M 1
FY2028 -KWD 2.260
-KWD 2.900 – -KWD 1.470
38 M 5

النقاط الرئيسية

Debt/Equity of 0.17 — conservative balance sheet
Negative free cash flow of -27.50M
PEG of 0.64 suggests growth is underpriced
Capital efficient — spends only 3.80% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)63.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-16.94%
ROIC-14.93%
Net Margin-31.23%
Op. Margin-43.83%

الأمان

Debt / Equity
0.17
Current Ratio6.12
Interest Coverage0.00

التقييم

P/E Ratio
-24.82
P/B Ratio4.11
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 63.54% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 123.67M Net Income (TTM) -38.63M
ROE -16.94% ROA -8.61%
Gross Margin 93.24% Operating Margin -43.83%
Net Margin -31.23% Free Cash Flow (TTM) -27.50M
ROIC -14.93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.17 Current Ratio 6.12
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -24.82 P/B Ratio 4.11
P/S Ratio 7.75 PEG Ratio 0.64
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 958.61M Enterprise Value 867.92M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 123.67M 75.62M 0.0 0.0 0.0
Net Income -38.63M -72.70M -135.35M -108.50M -73.96M
EPS (Diluted) -0.46 -0.98 -2.63 -2.30 -1.59
Gross Profit 115.32M 67.50M -6.22M 0.0 0.0
Operating Income -54.21M -81.11M -143.31M -112.38M -72.88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 448.66M 438.73M 303.76M 342.39M 366.33M
Total Liabilities 215.60M 215.80M 124.51M 70.98M 18.81M
Shareholders' Equity 233.06M 222.94M 179.25M 271.41M 347.52M
Total Debt 39.19M 42.72M 46.04M 47.00M 0.0
Cash & Equivalents 129.88M 224.25M 128.10M 54.91M 346.07M
Current Assets 393.19M 377.44M 236.21M 275.89M 348.67M
Current Liabilities 64.21M 156.95M 46.59M 25.57M 16.64M